Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

The Journal of Investigative Dermatology
Takashi MurakamiEiji Kobayashi

Abstract

With melanoma, as with many other malignancies, aberrant transcriptional repression is a hallmark of refractory cancer. To restore gene expression, use of a histone deacetylase inhibitor (HDACi) is expected to be effective. Our recent DNA micro-array analysis showed that the HDACi depsipeptide (FK228) significantly enhances gp100 antigen expression. Herein, we demonstrate that depsipeptide promotes tumor-specific T-cell-mediated killing of B16/F10 murine melanoma cells. First, by a quantitative assay of caspase-3/7 activity, a sublethal dose of depsipeptide was determined (ED50: 5 nM), in which p21(Waf1/Cip1) and Fas were sufficiently evoked concomitantly with histone H3 acetylation. Second, the sublethal dose of depsipeptide treatment with either a recombinant Fas ligand or tumor-specific T cells synergistically enhanced apoptotic cell death in B16/F10 cells in vitro. Furthermore, we found that depsipeptide increased levels of perforin in T cells. Finally, in vivo metastatic growth of B16/F10 in the lung was significantly inhibited by a combination of depsipeptide treatment and immune cell adoptive transfer from immunized mice using irradiated B16 cells and gp100-specific (Pmel-1) TCR transgenic mice (P<0.05, vs cell transfer ...Continue Reading

References

Jan 1, 1979·Journal of Surgical Oncology·J AventH F Seigler
Apr 4, 1973·Nature: New Biology·I J Fidler
Aug 23, 2000·Immunology Today·B SeligerS Ferrone
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Apr 26, 2002·Tissue Antigens·A WilliamsT Elliott
Sep 3, 2002·Cancer Cell·Heather L MaeckerAmato J Giaccia
May 27, 2003·Investigative Ophthalmology & Visual Science·Dino D KlisovicGuido Marcucci
Aug 2, 2003·Cancer Cell·Ricky W Johnstone, Jonathan D Licht
Aug 20, 2003·The Journal of Experimental Medicine·Willem W OverwijkNicholas P Restifo
Oct 29, 2003·The Journal of Experimental Medicine·Takashi MurakamiSam T Hwang
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Apr 9, 2004·The New England Journal of Medicine·Steven A Rosenberg
Jul 2, 2004·Nature Reviews. Cancer·Fran Balkwill
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Sep 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Steven A Rosenberg, Mark E Dudley
Feb 24, 2005·Journal of Immunotherapy·Paul Andrew Antony, Nicholas P Restifo
May 18, 2005·Oncogene·Thiyam Ramsing SinghRakesh K Srivastava
Nov 26, 2005·The Journal of Clinical Investigation·Jens DannullJohannes Vieweg
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Feb 16, 2006·Journal of Leukocyte Biology·Takashi Kakinuma, Sam T Hwang
Apr 20, 2006·Nature Reviews. Immunology·Luca GattinoniNicholas P Restifo
May 4, 2006·International Journal of Cancer. Journal International Du Cancer·Albert Zlotnik
Jun 14, 2006·Transplantation·Ichiro OhsawaEiji Kobayashi
Jul 25, 2006·Clinical Genitourinary Cancer·Walter M StadlerJohn A Thompson

❮ Previous
Next ❯

Citations

Nov 23, 2011·Immunology and Cell Biology·Karrune V WoanAlejandro Villagra
Oct 28, 2009·Nature Reviews. Immunology·Carl H JuneJames L Riley
Mar 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ailsa J ChristiansenRicky W Johnstone
Dec 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Begoña Comin-AnduixAntoni Ribas
Jun 15, 2010·Journal of Translational Medicine·Luca SigalottiMichele Maio
Oct 4, 2013·Immunotherapy·Elisabetta FrattaMichele Maio
Aug 19, 2014·Nature Reviews. Drug Discovery·Katrina J Falkenberg, Ricky W Johnstone
Oct 2, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yasuhiro TezukaTakashi Murakami
Jun 23, 2009·Current Opinion in Chemical Biology·Jay Hans KalinAlan Paul Kozikowski
Apr 9, 2013·Current Opinion in Immunology·Antoni Ribas, Jedd D Wolchok
Aug 16, 2011·Current Opinion in Immunology·Sergei V Kotenko
Apr 27, 2016·The FEBS Journal·Andrea NewboldRicky W Johnstone
Jun 2, 2017·Biological & Pharmaceutical Bulletin·Katsuyo SaitoYasuhiko Kobayashi
Dec 1, 2017·Immunotherapy·Tyler R McCawDonald J Buchsbaum
Sep 27, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alexander Badamchi-ZadehDan H Barouch
Nov 16, 2017·Oncotarget·Laurence BoothPaul Dent
Jun 27, 2009·Cancer Control : Journal of the Moffitt Cancer Center·Paul M HowellAdam I Riker
Jun 21, 2020·International Journal of Molecular Sciences·Sena KimJaebok Choi
Sep 10, 2020·Frontiers in Pharmacology·Sergi Herve AkoneRolf Müller
Aug 15, 2014·Oncotarget·Michiel KroesenGosse J Adema
Sep 8, 2016·Cold Spring Harbor Perspectives in Medicine·Yixuan Li, Edward Seto
Sep 16, 2020·Nature Reviews. Drug Discovery·Simon J HoggRicky W Johnstone
Jan 14, 2012·Expert Opinion on Therapeutic Targets·María Villa-Morales, José Fernández-Piqueras
Dec 7, 2019·Cancers·Lucillia BezuOliver Kepp
Jun 3, 2017·Clinical Epigenetics·Roberta MazzoneSergio Valente
Dec 30, 2016·Journal for Immunotherapy of Cancer·Tycel PhillipsRyan A Wilcox
Aug 2, 2017·Current Medicinal Chemistry·Li-Ming Zhao, Jie-Huan Zhang
May 6, 2014·Cancer Immunology Research·Deborah J L WongBegoña Comin-Anduix
Sep 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele MaioLuca Sigalotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis